Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for controlled colonization of the gut with engineered therapeutic bacteria, and are applying this to multiple disease areas as well as expanding our platform capabilities. Our lead program in enteric hyperoxaluria is currently in Phase 2 clinical trials, and we are focusing current research efforts on making a microbial cell therapy to treat inflammatory bowel disease (IBD).